Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study. Patients with advanced hepatocellular carcinoma (HCC; a type of liver cancer) have a median overall survival of less than l year, largely because of the absence of effective therapies.
by via Latest Science News -- ScienceDaily
by via Latest Science News -- ScienceDaily
No comments:
Post a Comment